Financial Performance - The company achieved operating revenue of 371 million RMB and a net profit of -202 million RMB during the reporting period [50]. - The revenue from chemical raw materials and products manufacturing was 237 million RMB, with a net profit of -25.63 million RMB, impacted by low downstream demand and rising raw material prices [50]. - The company reported a total of CNY 34,960,460.22 in investment income from long-term equity investments, a decrease from CNY 39,771,498.01 in the previous period [88]. - The company's main business revenue for the current period is CNY 604,539,544.17, with a cost of CNY 604,030,284.29, compared to CNY 248,717,404.89 in revenue and CNY 330,631,103.93 in cost for the previous period [80]. - The net profit attributable to the parent company for the current period is CNY -210,984,106.46, compared to CNY -166,087,675.85 in the previous period [88]. - The company reported a net loss attributable to shareholders for 2022 of approximately ¥210.98 million, compared to a loss of ¥166.09 million in 2021 [127]. - The total profit for the current period is CNY -242,972,366.09, with income tax expenses amounting to CNY 4,358,496.05 [95]. Assets and Liabilities - The total balance of short-term and long-term liabilities reached ¥638,678,103.04, compared to ¥407,875,811.50 previously, marking a significant increase of approximately 56.5% [28]. - The total balance of fixed assets was RMB 395,507,389.33, with ongoing procedures for property rights certification [16]. - The total balance of contract liabilities at the end of the period was ¥10,462,084.04, compared to ¥2,095,223.17 at the beginning, showing an increase of approximately 399.5% [31]. - The total deductible losses reported were approximately 573.9 million RMB, an increase from 390.9 million RMB in the previous year [54]. - The total assets at the end of 2022 were approximately ¥3.28 billion, a decrease of 0.85% from the previous year [127]. Cash Flow - The net cash inflow from investment activities amounted to ¥14,112,837.30, while the cash outflow was ¥7,004,900.00, resulting in a net cash flow of ¥7,112,837.30 from investment activities [159]. - The total cash inflow from financing activities reached ¥375,805,741.67, with cash outflows totaling ¥373,710,101.06, leading to a net cash flow of ¥2,095,640.61 from financing activities [159]. - The company's cash and cash equivalents increased by ¥1,756,291.90, ending the period with a balance of ¥1,904,716.80 [159]. Government Subsidies and Taxation - The total amount of government subsidies rose to ¥19,904,441.28, up from ¥12,913,902.88, representing an increase of about 54.5% [47]. - Government subsidies received in the current period total CNY 1,843,000.00, up from CNY 700,000.00 in the previous period [92]. - The company's total tax liabilities at the end of the period amounted to ¥8,288,307.25, compared to ¥4,780,828.51 at the beginning, showing an increase of approximately 73.5% [34]. Research and Development - The company has completed several R&D projects, including new fermentation processes for lauric acid, which aim to reduce costs and improve yield [143]. - Ongoing R&D projects include the development of activated carbon for acetone adsorption, achieving an adsorption rate of 22% [143]. - The company is developing a new generation of bio-based lauric acid production technology aimed at improving efficiency and reducing costs [172]. - The new generation of bio-based long-chain dicarboxylic acid production technology has improved fermentation efficiency beyond design levels, significantly reducing production costs and waste emissions [199]. Market Position and Strategy - The company is positioned in the bio-based materials manufacturing sector, which is gaining market dominance due to its environmentally friendly production methods [51]. - The company has plans for market expansion and new product development, although specific financial figures were not disclosed in the provided content [49]. - The company is focused on expanding its market presence for long-chain dicarboxylic acid production, utilizing a solvent-free process that aligns with national environmental policies [167]. - The company has established a mixed sales model combining direct sales, distribution, and consignment to enhance profitability and market reach [167]. Operational Efficiency - The company adopts a "sales-driven production" model for raw material procurement, ensuring efficient inventory management and cost control [198]. - Continuous technological research and application have led to a decrease in production costs and improved resource utilization efficiency [199]. - The production process is designed to be environmentally friendly, with no use of powdered activated carbon or organic solvents, aligning with low-carbon and sustainable development trends [199]. Employee and Management Expenses - Employee compensation increased significantly to ¥39,592,886.71 from ¥22,633,043.49, representing a growth of 74.8% [111]. - Management expenses increased by 199.55% year-on-year, primarily due to losses from the subsidiary's project suspension and increased capitalized salaries [178]. - Financial expenses rose by 186.81% year-on-year, largely due to increased capitalized interest from the subsidiary's construction projects [178].
宁科生物(600165) - 2022 Q4 - 年度财报(更正)